Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - posaconazole - gastro-resistant tablet - 100 milligram(s) - triazole derivatives; posaconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - posaconazole - gastro-resistant tablet - 100 milligram(s) - posaconazole

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - posaconazole - tablet, delayed release - posaconazole 100mg

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - posaconazole - gastro-resistant tablet - 100 milligram(s) - triazole derivatives; posaconazole

Canada - English - Health Canada

apotex inc - posaconazole - tablet (delayed-release) - 100mg - posaconazole 100mg - azoles

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - posaconazole 100mg;   - modified release tablet - 100 mg - active: posaconazole 100mg   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose opadry yellow 85f520152 propyl gallate sodium stearyl fumarate triethyl citrate xylitol - posaconazole juno is indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: - invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole. - oesophageal candidiasis or candidemia in patients with disease that is refractory to, or who are intolerant of, amphotericin b, fluconazole, or itraconazole. - fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. - coccidioidomycosis posaconazole juno is also indicated for the prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.